Pure Biologics

Executive Summary

Pure Biologics is a Polish biopharmaceutical company founded in 2013, specializing in the discovery and development of novel biologics for immuno-oncology. The company leverages proprietary antibody and aptamer technologies to build a pipeline of targeted therapies. Its lead programs have advanced into Phase 0 clinical trials, representing early-stage human testing to assess pharmacokinetics and target engagement. Pure Biologics' platform enables the generation of highly specific binding molecules, potentially offering advantages in safety and efficacy. The company is privately held and headquartered in Wroclaw, Poland. While still in early clinical development, Pure Biologics has demonstrated proof-of-concept in preclinical models and initiated first-in-human studies. The Phase 0 trials for two key candidates are expected to generate important data on dosing and biological activity. If successful, these programs could advance to Phase 1, positioning the company for potential partnerships or further financing. Pure Biologics operates in the competitive field of immuno-oncology, but its unique aptamer and antibody platforms may differentiate it. Near-term focus remains on advancing its pipeline and establishing clinical proof-of-mechanism.

Upcoming Catalysts (preview)

• Q3 2026Phase 0 clinical data readout for lead candidate75% success
• Q1 2027Initiation of Phase 1 trial for lead candidate60% success
• H2 2026Partnership or licensing deal for platform technology30% success